Holen Sie sich die Stockscreener-App
2.1298
0.01%
-0.0002
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
JP Morgan Chase & Company (JPM-N) QuotePress Release - The Globe and Mail
HeartBeam (NASDAQ: BEAT) To Present At JP Morgan 2025 Annual Healthcare Conference - Barchart
Heartbeam Inc (BEAT-Q) QuotePress Release - The Globe and Mail
HeartBeam to Showcase FDA-Cleared Revolutionary Heart Monitor at JP Morgan Healthcare Conference - StockTitan
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference - Business Wire
HeartBeam’s arrhythmia assessment system gains FDA 510(k) clearance - Yahoo! Voices
FDA clearance adds glow to Heartbeam prospects - BioWorld Online
HeartBeam Wins FDA Nod for Home High-Fidelity Heart Monitor - MPO-mag
HeartBeam announces FDA clearance for high-fidelity ECG system - TipRanks
Heartbeam stock soars to 52-week high, hits $3.48 - Investing.com
FDA clears HeartBeam's novel ECG system for arrhythmia - Investing.com India
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology - Business Wire
HeartBeam And 2 Other US Penny Stocks With Promising Potential - Simply Wall St
The Benchmark Company Announces Upcoming Discovery One-on-One Investor Conference - The Manila Times
HeartBeam rises on positive data from two studies on its vector-based technology - MSN
HeartBeam ECG technology shows promise in clinical studies By Investing.com - Investing.com Australia
HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference - BioSpace
HeartBeam Touts Data from Study of Vector-Based Tech - MPO-mag
HeartBeam ECG technology shows promise in clinical studies - Investing.com India
HeartBeam announces positive data from two studies at AHA - TipRanks
HeartBeam, Inc. (NASDAQ:BEATW) Short Interest Update - Defense World
HeartBeam, Inc. (NASDAQ:BEAT) Q3 2024 Earnings Call Transcript - Insider Monkey
HeartBeam (NASDAQ: BEAT) Advances Toward Commercialization of Cardiac Care Tech with FDA Submissions - Barchart
HeartBeam reports net loss of USD 5M in Q3 2024 - Medical Buyer
HeartBeam, Inc. Advances Cardiac Monitoring Solutions - TipRanks
HeartBeam Q3 Loss Widens to $5M as FDA Review Advances for Cardiac Tech | BEAT Stock News - StockTitan
Spotlight On US Penny Stocks In October 2024 - Simply Wall St
HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time - Business Wire
Tripp Investments Alters Stake in Betmakers - MSN
Severfield PLC Executes Share Buy-Back on LSE - MSN
HeartBeam, Inc. (BEAT): A Bull Case Theory - Insider Monkey
HeartBeam (NASDAQ: BEAT) Wins 2024 Digital Health Hub Award for Innovation in Cardiac Care - Barchart
HeartBeam Named “Rising Star” at the 6th Annual Digital Health Hub Foundation Awards - Business Wire
HeartBeam Appoints Robert Eno as New CEO - TipRanks
Upstart Holdings, Inc. (UPST) Registers a Bigger Fall Than the Market: Important Facts to Note - MSN
Diamondback Energy (FANG) Rises Yet Lags Behind Market: Some Facts Worth Knowing - MSN
Lifesaving Portable, AI Augmented Cardiac Monitoring - openPR
HeartBeam names Robert Eno as new CEO for growth phase - Investing.com
HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization - Business Wire
HeartBeam Appoints Robert Eno as Chief Exec - MPO-mag
Dr. Lance Myers Joins HeartBeam As Chief AI Scientist - MPO-mag
Dr. Lance Myers Joins HeartBeam as Chief AI Scientist - MPO-mag
Short Interest in HeartBeam, Inc. (NASDAQ:BEATW) Decreases By 17.6% - Defense World
HeartBeam appoints AI expert Lance Myers as Chief Scientist - Investing.com
HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist - Business Wire
Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation - Simply Wall St
Is HeartBeam (NASDAQ:BEAT) In A Good Position To Invest In Growth? - Yahoo Finance
Timothy Cruickshank named HeartBeam CFO - Medical Buyer
Heartbeam stock retains Speculative Buy rating despite near-term risks - Investing.com India
HeartBeam Names Timothy Cruickshank As CFO - MPO-mag
2.53%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):